Citigroup increases its price target to $110, up $16, on Buy-rated Allergan AGN ahead of AGN's R&D meeting on March 28th.
Citigroup says, "We expect the update to add confidence in AGN's ability to sustain a mid-teen long-term EPS growth rate beyond 2015. AGN's pipeline, its broader emerging markets commercial footprint, and underappreciated operating leverage are placing upward pressure on our estimates. We conservatively model a 2011-2015E EPS CAGR of 12%+. Our $110 PT assumes AGN trades at 22.6x our 2013E EPS of $4.86 (vs. its historical median P/E of 26.7x); our DCF yields ~$114/share."
AGN closed at $94.74 a share on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in